share_log

EXCLUSIVE: Lineage Cell Establishes New R&D Facility In US, Expands Israel-Based Facility

EXCLUSIVE: Lineage Cell Establishes New R&D Facility In US, Expands Israel-Based Facility

独家报道：Lineage Cell在美国建立新的研发设施，扩大以色列设施
Benzinga Real-time News ·  2022/10/03 07:43
  • Lineage Cell Therapeutics Inc (NYSE:LCTX) has opened a new research and development facility in Carlsbad, California.
  • What Happened: The new Carlsbad facility will broaden the company's R&D capabilities in the U.S. and support the development of current and future allogeneic cell transplant programs.
  • The company has also announced the expansion of its manufacturing facility in Jerusalem, Israel, which will increase its infrastructure, including developing and optimizing larger-scale clinical manufacturing processes and continued execution under its ongoing collaboration with Roche Holdings AG (OTC:RHHBY) and Genentech for RG6501 (OpRegen).
  • RG6501 is a retinal pigment epithelium cell replacement therapy that has completed enrollment in a Phase 1/2a trial for geographic atrophy secondary to age-related macular degeneration.
  • Why It Matters: "The additional capacity also can help us become an even more capable partner in prospective alliances for new products and allow us to explore additional uses for our current cell transplant programs," commented Brian Culley, Lineage CEO.
  • "The modest investments we are making today, partially offset by the termination of the lease for our research facility in Alameda, California, in January of next year, will help centralize our operations and put us in a position of greater readiness for future success," Culley added.
  • Price Action: LCTX shares closed lower by 1.74% at $1.13 on Friday.
  • 世系细胞治疗公司(纽约证券交易所股票代码：LCTX)在加利福尼亚州卡尔斯巴德开设了一家新的研发机构。
  • 发生的事情：新的卡尔斯巴德工厂将扩大该公司在美国的研发能力，并支持当前和未来异基因细胞移植计划的发展。
  • 该公司还宣布扩大其在以色列耶路撒冷的制造设施，这将增加其基础设施，包括开发和优化更大规模的临床制造流程，并在其持续合作下继续执行罗氏控股公司(场外交易：RHHBY)和基因泰克用于RG6501(OpRegen)。
  • RG6501是一种视网膜色素上皮细胞替代疗法，已经完成了1/2a期试验，用于治疗继发于老年性黄斑变性的地理萎缩。
  • 为什么这很重要：Lineage首席执行官布莱恩·卡利评论说：“额外的产能还可以帮助我们在未来的新产品联盟中成为一个更有能力的合作伙伴，并使我们能够探索我们目前细胞移植计划的其他用途。”
  • 卡尔利补充说：“我们今天进行的少量投资，部分抵消了明年1月终止我们在加利福尼亚州阿拉米达的研究设施的租约，这将有助于集中我们的业务，使我们为未来的成功做好更好的准备。”
  • 价格行动：LCTX股价周五收低1.74%，报1.13美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发